ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2023
Kidney outcome after mild to moderate COVID-19.
Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 20 citations in OpenAlex.
- Sex differences in blood pressure and hypertension through adulthood.Clinical kidney journal · 2026Article
- Biopsychosocial Correlates of Somatic Symptom Burden in CKD: Results of the Hamburg City Health Study.Kidney360 · 2026Article
- Association of periodontitis with reduced kidney function and albuminuria in early chronic kidney disease: a population-based study.International journal of oral science · 2026Article
- Dickkopf-3 (DKK3) and the Progression of Diabetic Kidney Disease in Primary Health Care.Diabetes · 2026Article
- Overweight/obesity accelerates proteinuria progression in type 2 diabetes post-COVID-19: a comparison with a pre-pandemic uninfected cohort.Frontiers in endocrinology · 2026Article
- Impact of COVID-19 on chronic kidney disease progression in non-dialysis patients: a retrospective cohort study in Palestine.Annals of medicine · 2025Article
- Long COVID and the kidney.Nature reviews. Nephrology · 2025Review
- Long-term renal consequences of COVID-19. Emerging evidence and unanswered questions.International urology and nephrology · 2025Review
- Estimated glomerular filtration rate in post COVID-19 patients at 3-6 months and 12-18 months after infection.Renal failure · 2025Article
- Long-Term Renal Outcomes Among COVID-19 ICU Survivors Admitted With Acute Kidney Injury.Cureus · 2025Article
- Nicotinism vs. Glomerulopathies-Smoking as a Risk Factor for Primary Glomerulopathies.Antioxidants (Basel, Switzerland) · 2025Review
- Long-term kidney outcomes after COVID-19: a matched cohort study using the OpenSAFELY platform.The Lancet regional health. Europe · 2025Article
- Increased Measured GFR and Proteinuria in Children with Previous Infection by SARS-CoV-2: Should We Be Concerned?Microorganisms · 2025Article
- Long term outcomes of patients with chronic kidney disease after COVID-19 in an urban population in the Bronx.Scientific reports · 2025Article
- Kidney damage associated with COVID-19: from the acute to the chronic phase.Renal failure · 2024Review
- The hidden impact: the rate of nicotine metabolism and kidney health.Frontiers in endocrinology · 2024Article
- The impact of SARS-CoV-2 infection on renal function in patients with biopsy-proven kidney diseases.PloS one · 2023Article
- Renal long COVID-19: an ongoing debate requiring robust evidence.Jornal brasileiro de nefrologiaArticle
- Comparative 3-Year Allograft Outcomes for Recipients of Kidneys From SARS-CoV-2 NAT-Positive Donors.Transplant infectious disease : an official journal of the Transplantation SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a remarkable kidney tropism. While kidney effects are common in severe coronavirus disease 2019 (COVID-19), data on non-severe courses are limited. Here we provide a multilevel analysis of kidney outcomes after non-severe COVID-19 to test for eventual kidney sequela.
methodsThis cross-sectional study investigates individuals after COVID-19 and matched controls recruited from the Hamburg City Health Study (HCHS) and its COVID-19 program. The HCHS is a prospective population-based cohort study within the city of Hamburg, Germany. During the COVID-19 pandemic the study additionally recruited subjects after polymerase chain reaction-confirmed SARS-CoV-2 infections. Matching was performed by age, sex and education. Main outcomes were estimated glomerular filtration rate (eGFR), albuminuria, Dickkopf3, haematuria and pyuria.
resultsA total of 443 subjects in a median of 9 months after non-severe COVID-19 were compared with 1328 non-COVID-19 subjects. The mean eGFR was mildly lower in post-COVID-19 than non-COVID-19 subjects, even after adjusting for known risk factors {β = -1.84 [95% confidence interval (CI) -3.16 to -0.52]}. However, chronic kidney disease [odds ratio (OR) 0.90 (95% CI 0.48-1.66)] or severely increased albuminuria [OR 0.76 (95% CI 0.49-1.09)] equally occurred in post-COVID-19 and non-COVID-19 subjects. Haematuria, pyuria and proteinuria were also similar between the two cohorts, suggesting no ongoing kidney injury after non-severe COVID-19. Further, Dickkopf3 was not increased in the post-COVID-19 cohort, indicating no systematic risk for ongoing GFR decline [β = -72.19 (95% CI -130.0 to -14.4)].
conclusionWhile mean eGFR was slightly lower in subjects after non-severe COVID-19, there was no evidence for ongoing or progressive kidney sequela.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.